Cytosorbents Consensus Price Target Increased by 1,900% to $48.45

The aggregate one-year analyst price target for Cytosorbents was revised to $48.45 per share from $2.42 on August 25, 2026, a 1,900% increase. The figure reflects analyst targets compiled by Fintel and signals a sharply more optimistic valuation outlook, though the article provides no underlying earnings, clinical, or operational catalyst.